Lynparza (olaparib) / Merck (MSD), AstraZeneca  >>  Phase 3
Welcome,         Profile    Billing    Logout  

40 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynparza (olaparib) / Merck (MSD), AstraZeneca
ACTRN12618000498291: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients.

Recruiting
3
110
 
The University of Sydney, Cancer Australia, AstraZeneca, Cancer Research UK
Ovarian Cancer, Fallopian tube Cancer, Peritoneal Cancer
 
 
NCT01924533: Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Checkmark GOLD trial for 2nd-line gastric cancer
May 2016 - May 2016: GOLD trial for 2nd-line gastric cancer
Checkmark Completion of enrollment in P3 GOLD trial for 2nd-line gastric cancer
Aug 2015 - Aug 2015: Completion of enrollment in P3 GOLD trial for 2nd-line gastric cancer
Completed
3
525
Japan, RoW
Olaparib, Paclitaxel, Placebo
AstraZeneca
Gastric Cancer
04/16
03/23
SOLO-2, NCT01874353 / 2013-001211-75: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Checkmark From SOLO2 trial in relapsed BRCA mutated ovarian cancer at ASCO 2020
Jun 2020 - Jun 2020: From SOLO2 trial in relapsed BRCA mutated ovarian cancer at ASCO 2020
Checkmark From SOLO 2 trial in first-line ovarian cancer at ASCO 2020
May 2020 - May 2020: From SOLO 2 trial in first-line ovarian cancer at ASCO 2020
Checkmark QoL data in germline BRCA1/2-mutated ovarian cancer
More
Active, not recruiting
3
327
Europe, Canada, Japan, US, RoW
Olaparib 300mg tablets, Placebo to match olaparib 300mg
AstraZeneca, European Network of Gynaecological Oncological Trial Groups (ENGOT), Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
09/16
12/24
OlympiAD, NCT02000622 / 2013-005137-20: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Checkmark In gBRCA-mutated HER2-negative metastatic breast cancer
Apr 2018 - Apr 2018: In gBRCA-mutated HER2-negative metastatic breast cancer
Checkmark OlympiAD trial for BRCAm metastatic breast cancer at ASCO 2017
Jun 2017 - Jun 2017: OlympiAD trial for BRCAm metastatic breast cancer at ASCO 2017
Active, not recruiting
3
302
Europe, Japan, US, RoW
Olaparib, Physician's choice chemotherapy
AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
12/16
12/24
2017-000161-75: ICON9 is a research study investigating patients with recurrent ovarian, fallopian tube or primary peritoneal cancer, who have had their tumour shrunk by chemotherapy. The study will address whether such patients may benefit from maintenance treatment with two new anti-cancer, orally-administrated drugs called olaparib and cediranib.

Not yet recruiting
3
618
Europe
Olaparib, Cediranib, AZD2171 Maleate, Film-coated tablet, Lynparza
University College London, Cancer Research UK, AstraZeneca UK Limited
High grade serous or endometrioid ovarian, fallopian and peritoneal cancer, Ovarian, fallopian and peritoneal cancer, Diseases [C] - Cancer [C04]
 
 
SOLO-1, NCT01844986 / 2013-001551-13: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Checkmark Seven-year follow-up from P3 SOLO-1 trial for ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Seven-year follow-up from P3 SOLO-1 trial for ovarian cancer at ESMO 2022
Checkmark Presentation of data from SOLO-1 trial in 1L ovarian cancer at SGO 2021
May 2021 - May 2021: Presentation of data from SOLO-1 trial in 1L ovarian cancer at SGO 2021
Checkmark Presentation of data from SOLO-1 trial in 1L ovarian cancer at ESMO 2020
More
Active, not recruiting
3
450
Europe, Canada, Japan, US, RoW
Olaparib 300mg tablets
AstraZeneca, GOG Foundation, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
05/18
08/28
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
POLO, NCT02184195 / 2014-001589-85: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Checkmark From POLO trial for gBRCAm and metastatic pancreatic cancer at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From POLO trial for gBRCAm and metastatic pancreatic cancer at ASCO 2019 [screenshot]
Checkmark From POLO trial in 1L gBRCA+ pancreatic cancer
Feb 2019 - Feb 2019: From POLO trial in 1L gBRCA+ pancreatic cancer
Completed
3
154
Europe, Canada, US, RoW
Olaparib, Placebo
AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
01/19
01/23
PROfound, NCT02987543 / 2016-000300-28: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer ( Study)

Checkmark Quality of life data from PROfound trial in mCRPC
Feb 2022 - Feb 2022: Quality of life data from PROfound trial in mCRPC
Checkmark Follow-up data from PROfound trial for metastatic castration resistant prostate cancer at ESMO 2020
Sep 2020 - Sep 2020: Follow-up data from PROfound trial for metastatic castration resistant prostate cancer at ESMO 2020
Checkmark Data from PROfound trial for mCRPC at ESMO 2020
More
Completed
3
387
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, enzalutamide, XTANDI, abiraterone acetate, ZYTIGA
AstraZeneca, Merck Sharp & Dohme LLC, Foundation Medicine, Inc., Myriad Genetics, Inc.
Metastatic Castration-resistant Prostate Cancer
06/19
02/23
2018-004720-11: Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Ongoing
3
792
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), Pembrolizumab, Olaparib, ALIMTA, Pemetrexed, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, Powder for concentrate for solution for infusion, KEYTRUDA® (pembrolizumab, MK-3475), ALIMTA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Stage IV lung cancer condition, Stage IV lung cancer condition, Diseases [C] - Cancer [C04]
 
 
NRG-GY004, NCT02446600: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Checkmark From GY004 trial in combination with cediranib for recurrent platinum sensitive ovarian cancer
Mar 2020 - Mar 2020: From GY004 trial in combination with cediranib for recurrent platinum sensitive ovarian cancer
Active, not recruiting
3
579
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), AstraZeneca, NRG Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
02/20
08/24
2019-000698-22: Olaparib +/- bevacizumab in CRC with SD/PR/CR from FOLFOX with bevacizumab.

Ongoing
3
525
Europe
Olaparib, MK-7339, Film-coated tablet, Concentrate for solution for infusion, Solution for injection/infusion, Avastin (Bevacizumab), 5-Fluorouracil-Ebewe (5-FU)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab, Advanced Metastatic Colorectal Cancer (Has not progressed after completing at least 6 prior induction cycles of FOLFOX + Bevacizumab and can no longer tolerate any components of FOLFOX), Diseases [C] - Cancer [C04]
 
 
OlympiA, NCT02032823 / 2013-003839-30: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Hourglass Apr 2023 - Jun 2023 : Acceptance of regulatory submission fin China for breast cancer (based on OlympiA trial)
Checkmark From OlympiA trial in germline BRCA-mutated, HER2-negative high-risk early breast cancer
Mar 2022 - Mar 2022: From OlympiA trial in germline BRCA-mutated, HER2-negative high-risk early breast cancer
Checkmark From OlympiA trial for breast cancer at ASCO 2021
Jun 2021 - Jun 2021: From OlympiA trial for breast cancer at ASCO 2021
More
Active, not recruiting
3
1836
Europe, Canada, Japan, US, RoW
Olaparib, Lynparza, Placebo
AstraZeneca, Breast International Group, Frontier Science & Technology Research Foundation, Inc., NRG Oncology, Myriad Genetic Laboratories, Inc., Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet, Merck Sharp & Dohme LLC
Breast Cancer
03/20
05/29
2021-000245-41: Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups. Trattamento con Olaparib oltre la progressione confrontato con chemioterapia a base di platino dopo citoriduzione secondaria in pazienti con recidiva da carcinoma ovarico. MITO 35b, studio di fase 3 randomizzato: un progetto dei Gruppi MITO-MANGO.

Ongoing
3
200
Europe
CARBOPLATINO, LYNPARZA, Cisplatino, Gemcitabina, Paclitaxel, Doxorubicina Liposomiale Pegilata, [CARBOPLATINO], [LYNPARZA], [Cisplatino], [Gemcitabina], [Paclitaxel], [Doxorubicina Liposomiale Pegilata], Concentrate for solution for infusion, Film-coated tablet, LYNPARZA - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE, LYNPARZA - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Diseases [C] - Cancer [C04]
 
 
PROPEL, NCT03732820 / 2018-002011-10: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Jan 2022 - Dec 2023: Acceptance of regulatory submission in China in combination with abiraterone for prostate cancer (based on PROpel trial)
Checkmark Data from PROPEL trial in combination with abiraterone for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Data from PROPEL trial in combination with abiraterone for mCRPC at ESMO 2022
Checkmark Data from PROPEL trial in combination with abiraterone for mCRPC
Jun 2022 - Jun 2022: Data from PROPEL trial in combination with abiraterone for mCRPC
More
Active, not recruiting
3
895
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, abiraterone acetate, Zytiga
AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
07/21
04/26
KEYLYNK-010, NCT03834519 / 2018-004118-16: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/)

Not Appicable Jan 2022 - Dec 2022 : From KEYLYNK-010 trial in combination with Lynparza for metastatic CRPC
Checkmark Presentation of data from KEYLYNK-010 trial for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYLYNK-010 trial for mCRPC at ESMO 2022
Completed
3
793
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Olaparib, MK-7339, AZD-2281, LYNPARZA®, Abiraterone acetate, ZYTIGA®, CB-7630, JNJ-212082, Prednisone, Enzalutamide, XTANDI®, MDV-3100, ASP-9785, Prednisolone
Merck Sharp & Dohme LLC
Prostatic Neoplasms
03/22
01/24
LYNK-003, NCT04456699 / 2019-000698-22: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/)

Calendar Jan 2024 - Dec 2024: Data from LYNK-003 trial for 1L colorectal cancer
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for CRC (based on LYNK-003 trial)
Checkmark Termination of P3 LYNK-003 trial in unresectable or metastatic CRC
Jul 2022 - Jul 2022: Termination of P3 LYNK-003 trial in unresectable or metastatic CRC
Completed
3
335
Europe, Canada, Japan, US, RoW
Olaparib, LYNPARZA^TM, 5-FU, Fluorouracil, Adrucil, Efudex, Bevacizumab, MVASI^TM, Avastin, Capecitabine, XELODA^®, Leucovorin/ levoleucovorin, Folinic Acid, Fusilev^®, Khapzory^TM
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Metastatic Colorectal Cancer
03/23
11/23
DUO-O, NCT03737643 / 2017-004632-11: Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for 1L ovarian cancer (based on DUO-O trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US in combination with Imfinzi for 1L ovarian cancer (based on DUO-O trial)
Jan 2023 - Jun 2023: Data from DuO-O trial in combination with Imfinzi for advanced ovarian cancer
Active, not recruiting
3
1407
Europe, Canada, Japan, US, RoW
Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
AstraZeneca, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Inc. (GOG Foundation), Myriad Genetic Laboratories, Inc.
Advanced Ovarian Cancer
09/23
05/28
DUO-E, NCT04269200 / 2019-004112-60: Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for endometrial cancer (based on DuO-E trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for endometrial cancer (based on DuO-E trial)
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in Japan in combination with Imfinzi (based on DuO-E trial) for 1L endometrial cancer
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in Japan in combination with Lynparza (based on DuO-E trial) for 1L endometrial cancer
Jul 2023 - Dec 2023: Data from DUO-E trial in combination with Imfinzi for 1L endometrial cancer
More
Active, not recruiting
3
805
Europe, Canada, Japan, US, RoW
olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
AstraZeneca, The Gynecologic Oncology Group (GOG) Foundation Inc, The European Network for Gynaecological Oncological Trial groups (ENGOT)
Endometrial Neoplasms
03/25
03/25
L-MOCA, NCT03534453: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Active, not recruiting
3
229
RoW
Olaparib 300mg tablets
AstraZeneca
Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive
12/24
12/24
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
ENGOT-ov43, NCT03740165 / 2018-001973-25: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001//GOG-3036)

Hourglass Jan 2023 - Dec 2023 : From KEYLYNK-001 trial in combination with Keytruda for 1L non epithelial BRCA ovarian cancer
Active, not recruiting
3
1367
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo for pembrolizumab, normal saline or dextrose, Carboplatin, PARAPLATIN®, Paclitaxel, TAXOL®, Olaparib, MK-7339, LYNPARZA®, Placebo for olaparib, Bevacizumab, AVASTIN®, Docetaxel
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
08/24
05/26
Subito, NCT02810743 / 2016-002493-13: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Active, not recruiting
3
174
Europe
ddAC-CP-Olaparib, ddAC-mini CTC
The Netherlands Cancer Institute
Breast Cancer
10/24
12/33
ICON9, NCT03278717: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London
Ovarian Cancer
12/23
12/23
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
01/26
PROpel Study, NCT05171816: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Active, not recruiting
3
108
RoW
olaparib, Lynparza, abiraterone acetate, Zytiga
AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
01/24
04/26
KEYLYNK-008, NCT03976362 / 2018-004721-88: A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/)

Calendar Apr 2024 - Jun 2024: From KEYLYNK-008 trial +/- Lynparza for 1L metastatic NSCLC
Active, not recruiting
3
591
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, PARAPLATIN®, Paclitaxel, TAXOL®, ONXAL™, Nab-paclitaxel, ABRAXANE®, Olaparib, LYNPARZA®, Placebo
Merck Sharp & Dohme LLC
Carcinoma, Squamous Cell, Non-small-cell Lung
09/23
03/25
MONO-OLA1, NCT04884360 / 2020-005960-68: D9319C00001- 1L OC Mono Global RCT

Calendar Jan 2024 - Dec 2024: Data from MONO-OLA1 trial for BRCAwt advanced ovarian cancer
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L BRCAwt ovarian cancer (based on MONO-OLA1 trial)
Recruiting
3
420
Europe, RoW
Olaparib, Matching placebo
AstraZeneca
Ovarian Cancer
07/24
07/25
KEYLYNK-006, NCT03976323 / 2018-004720-11: Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, )

Calendar Jul 2024 - Sep 2024: From KEYLYNK-006 trial +/- Lynparza for 1L metastatic non squamous NSCLC
Active, not recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, PLATINOL®-AQ, Olaparib, LYNPARZA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Carcinoma, Non-squamous Non-small-cell Lung
02/24
01/25
ROSY-O, NCT04421963 / 2019-003777-26: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

Enrolling by invitation
3
292
Europe, Canada, US, RoW
Olaparib
AstraZeneca
Ovarian Cancer, Breast Cancer
12/24
12/24
KEYLYNK-012, NCT04380636 / 2019-003237-41: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/)

Calendar Jan 2026 - Dec 2026: Data from KEYLINK-012 trial in combination with Lynparza for stage III NSCLC
Active, not recruiting
3
870
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, LYNPARZA®, MK-7339, AZD2281, KU-0059436, Placebo for olaparib, Etoposide, VEPESID®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, Paclitaxel, TAXOL®, Pemetrexed, ALIMTA®, Thoracic Radiotherapy, Durvalumab, IMFINZI®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
07/26
02/27
KEYLYNK-013, NCT04624204 / 2019-003616-31: Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/)

Recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab 200 mg, MK-3475, KEYTRUDA®, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, MK-7339, LYNPARZA®, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Merck Sharp & Dohme LLC
Small Cell Lung Cancer
10/27
10/27
MITO 35B, NCT05255471: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

Recruiting
3
200
Europe
Olaparib, Chemotherapy drug
National Cancer Institute, Naples
Ovarian Cancer
01/28
01/28
TROPION-Breast04, NCT06112379: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Recruiting
3
1728
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Pembrolizumab, KEYTRUDA®, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord, Olaparib, LYNPARZA®
AstraZeneca, Daiichi Sankyo
Breast Cancer
03/28
08/30
NCT04024254: A Study of Serum Folate Levels in Patients Treated With Olaparib

Active, not recruiting
2/3
10
US
Folic Acid Tablet
Rush University Medical Center
Ovarian Cancer, Breast Cancer, Folic Acid Deficiency
09/24
12/24
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
COCOS, NCT02502266: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Hourglass Jul 2023 - Dec 2023 : Data from COCOS (GY005) trial trial in combination with Recentin for recurrent platinum r/r ovarian cancer
Active, not recruiting
2/3
562
Canada, Japan, US, RoW
Cediranib, AZ-D2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Questionnaire Administration, Topotecan, Hycamptamine, Topotecan Lactone, Topotecan Hydrochloride, Evotopin, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI), Canadian Cancer Trials Group, NRG Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
06/24
06/24
RAINBO, NCT05255653: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Recruiting
2/3
1615
Europe, Canada
Olaparib, Lynparza, Pelvic external beam radiotherapy, EBRT, Chemotherapy, Cisplatin, Carboplatin, Paclitaxel, Durvalumab, Imfinzi, Medroxyprogesterone Acetate, Progestogen, Megestrol Acetate, Vaginal brachytherapy, Observation
Leiden University Medical Center, Institute Gustave Roussy (sponsor p53abn-RED trial), Leiden University Medical center (sponsor MMRd-GREEN trial), University College London (sponsor NSMP-ORANGE trial), Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial), Dutch Gynaecological Oncology Group, Comprehensive Cancer Centre The Netherlands, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR)
Endometrial Cancer
01/30
01/31
A092104, NCT05633381: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Recruiting
2/3
70
US
Olaparib, 763113-22-0, Temozolomide, 85622-93-1, Trabectedin, 114899-77-3, Pazopanib, 444731-52-6, 790713-33-6
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Suspended
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET-743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30

Download Options